STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

Argenx said Thursday that its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren’s disease, a chronic autoimmune disorder.

It’s an unusual setback for Argenx, which has racked up a series of wins in autoimmune disorders en route to becoming one of the world’s largest biotechs by market cap. 

Argenx’s stock slipped 13% Thursday morning. 

Continue to STAT+ to read the full story…